Regulatory, Compliance, and More.Abstract
Objective: The development of a vaccine against Epstein-Barr Virus (EBV) is crucial due to its association with various cancers and diseases such as Burkitt lymphoma, Hodgkin lymphoma, nasopharyngeal cancer, and multiple sclerosis. Despite the slow progress, significant strides have been made in identifying potential vaccine targets and adjuvants. Glycoprotein 350 (gp350) on the surface of EBV is a primary focus, with studies indicating that multimeric gp350 vaccines elicit stronger immune responses than monomeric versions. Human clinical trials have shown partial protection using gp350-based vaccines, but challenges remain in achieving long-lasting immunity and complete protection. Future vaccines may need to incorporate additional epitopes beyond gp350, such as gH/gL, gB, and gp42 glycoproteins. This article summarizes current research and highlights the ongoing efforts to develop an effective and safe EBV vaccine.